kiyatec.comKIYATEC

About Us Our Science Bibliography News Team Contact Oncology Drug Response Profiling Advanced 3D Cell Culture Services Click to Scroll and Learn More Predicting in vivo cancer drug efficacy through precision ex vivo response profiling Learn More Learn More Clinical Testing Services Drug Development Services About Us We leverage our proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. Drug Development Services: We work with leading biopharmaceutical companies to unlock response dynamics ( ex vivo efficacy) for their investigational cancer drug candidates in preclinical testing and subsequent clinical trials. Clinical Testing Services (CLIA-certified laboratory): In 2019 we published of our assay’s analytical validation and clinical evidence of its predictive performance. Currently we are further validating drug response-predictive clinical assays as well as undertaking investigator-initiated studies in ovarian cancer, high-grade glioma, breast cancer and rare tumors. Our Science Our ex vivo 3D cell culture platforms enable us to utilize live cancer cells from surgical or biopsy tissue specimens in order to create a patient-specific in vivo-like tumor and immune microenvironment, outside the body, in which to accurately model and assess response ( ex vivo efficacy) to investigational and approved cancer therapies . Ex vivo 3D cell culture is unique in that it maximizes patient relevance in the in vitro assessment of drug-on-tumor cell interaction prior to in vivo therapy administration. We are constantly expanding the scientific boundaries of ex vivo 3D cell culture capability. Our evidence base spans most solid tumor types and cancer drug classes , offering unparalleled predictive utility in the clinic and in the drug development laboratory. Key Citations 3D Cell Culture Platform Validation Redefining Personalized Medicine by Drug Response Profiling of Patient-Derived Spheroids Breast Cancer Complex, Patient-Derived, Multi-Cell Type, 3D Models of Breast Cancer for Personalized Prediction of Therapeutic Response 3D Modeling of Immune Cell Interactions in Breast Cancer and Prediction of Immunotherapy Response Perfused 3D Tri-Culture Breast Cancer Microtumors for Accurate Prediction of Drug Response Brain Cancer Prospective Validation of an Ex Vivo 3D Assay for Prediction of Temozolomide Response in Glioblastoma Ex Vivo Models of Glioblastoma: A Comparison of 3D Tissues and Patient-Derived Xenografts to Clinical Response Profiling Patient-Specific Glioblastoma Drug Response In Vitro Using Complex 3D Microtumors Development of an in Vitro 3D Glioblastoma Model System for Patient-Specific Drug Response Profiling A Complex 3D Model of Glioblastoma for Patient-Specific Drug Response Profiling Clinical Applicability of Individualized Drug Response Profiling Utilizing Ex Vivo Tissue-Derived 3D Cell Culture Assays in High Grade Glioma: A Single Institution Case Series Using 3D-PREDICT Results Ex Vivo Testing of Patient-Derived Xenografts (PDX) Establishment and characterization of paired palbociclib-sensitive and resistant luminal A breast PDX models Enhancing Drug Discovery & Development Throughput Without Sacrificing Predictivity: ex vivo 3D Drug Response Profiling Using PDX Immuno-Oncology Multifaceted functional assessment of checkpoint inhibitor efficacy using 3D tumor spheroids PARP inhibition in combination with pembrolizumab enhances cytotoxicity in ovarian cancer patient-derived 3D spheroids Predicting Patient Response to Checkpoint Blockade Therapy Using In Vitro 3D Culture Predicting Patient Response to Immuno-Oncology Agents In Vitro Using 3D Cultures 3D Tissue Models to Predict Patient-Specific Responses to immuno-Oncology Agents Complex, 3D Tissues for Modeling the Immune Response in Cancer and Predicting the Activity of Immunotherapies In Vitro Platelets Closed-Loop Bioreactor for In Vitro Platelet Production from Hematopoietic Stem Cells Ovarian Cancer Prospective Validation of an Ex Vivo , Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer Rare Tumors The Perfused 3DKUBE™ Rare Tumor Assay Models In Vivo Drug Response Paired Isolation and Expansion of CSC and CTC from Primary Small Cell Lung Cancer Patient Tissue and Blood Using the 3DKUBE® Bioreactor Platform Marker Free Isolation and Expansion of Cancer Stem Cells from Small Cell Lung Cancer For Access to Citations Please enable JavaScript in your browser to complete this form. Name * First Last Phone Email * I am a: * Laboratory scientist Clinician Patient Caregiver Investor Journalist Other Please check all that apply * I would like to receive more information about drug development services I would like to receive more information about clinical testing services I would like someone from to contact me Please specify your request: Website Submit News Study Shows Typical Cancer-Free Survival Doubled for Recurrent Brain Cancer Patients when ’s Test Informed Therapy Selection December 17, 2020 University of Arkansas for Medical Sciences Joins Clinical Study of Test to Predict Pre-Treatment, Patient-Specific Response to Ovarian Cancer Drugs June 25, 2020 Cancer Diagnostics Innovator Advancing Functional Ex Vivo 3D Cell Culture Models that Reveal Response Dynamics to Immuno-Oncology Drugs June 22, 2020 Cancer Diagnostics Innovator Adds Clinical and Reimbursement Experience to Board as Clinical Testing Validation Progresses May 4, 2020 Cancer Diagnostics Innovator Expands Services to Help Relieve COVID-19 Testing Bottleneck April 1, 2020 VA Portland Health Care System Joins Clinical Study of Test to Predict Pre-Treatment, Patient-Specific Response to Glioblastoma Drugs March 2, 2020 Secures Investment from Life Sciences Venture Fund Esperante to Fuel Clinical Assay Validation Efforts January 8, 2020 CarThera and Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Cancer November 18, 2019 To Present Immuno-Oncology Response Characterization at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting November 5, 2019 Announces Addition of Capital Health as Clinical Site in Trial to Predict GBM Patient-Specific Response to Cancer Drugs Prior to Treatment August 13, 2019 Assay Hits the Mark in Study to Predict Patient Response to First Line Ovarian Cancer Drugs August 1, 2019 Announces $3 Million Initial Closing of Series B2 Preferred Stock Financing and New Investor LabCorp May 1, 2019 Selected for University Innovation and Entrepreneurship Startup Showcase on Capitol Hill April 10, 2019 to Present Data on Advanced Ex Vivo 3D Cell Culture Technology to Aid Cancer Patient Care and Drug Development at AACR 2019 March 28, 2019 Inova Health System and Roswell Park Comprehensive Cancer Center Join Clinical Trial to Predict Patient Response to Cancer Drugs Prior to Treatment March 15, 2019 Adds Oregon Health & Science University to Study to Predict Response to Cancer Therapy Prior to Treatment February 6, 2019 Announces Enrollment of First Patients in Clinical Trial to Predict Personalized Response to Oncology Drugs Prior to Treatment June 20, 2018 Strengthens Leadership Team with Appointment of Vice Presidents of Clinical Affairs and Commercial Operations May 29, 2018 Team Executive Team Matthew R. Gevaert, Ph.D. : CEO & Co-founder Dr. Matthew (Matt) Gevaert is the Chief Executive Officer and a co-founder of , Inc. Under Matt’s leadership and support of an incredible team, has earned national recognition for its progress towards accurately modeling and predicting cancer patient response to drug therapies prior to treatment. Based on 3D cell culture technology, the company has pioneered a novel “in-hospital startup” model to solve intrinsically complex healthcare problems for the betterment of cancer patients, developing elegant solutions that will ultimately work both for the hospital...